Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2012

View Archived Issues

Investigators discover two novel genes related to ALS

Amgen presents novel series of beta-secretase inhibitors

GeoVax presents promising phase II results for their HIV vaccines

Actelion designs novel orexin receptor antagonists

Research at Actelion yields new P2X7 receptor antagonists

Vertex Pharmaceuticals patents Na(V) channel inhibitors

University of Pittsburg presents new radioprotectants

Cystic Fibrosis Foundation Therapeutics and Pulmatrix enter collaboration

Novel PDE10A inhibitors created at Allergan

Georgetown University presents new AGBL2 inhibitors

Biodel advances with phase II insulin study

Novo-23 presented as novel antitubercular drug candidate with a new antibiotic target

RQ-00201894 selected for preclinical evaluation

DMC recommends Celsion's HEAT Study continuation

Phase III study of Japanese cedar pollinosis immunotherapy meets primary endpoint

Boehringer Ingelheim begins expanded access program for afatinib

Cornerstone Therapeutics provides regulatory update on lixivaptan

Dara BioSciences acquires exclusive U.S. right to Gelclair

Oncodesign and Sanofi enter kinase research collaboration

Treanda now available in Canada

Pearl Therapeutics identifies optimal dose of COPD treatment candidate

RepliGen withdraws MAA for SecreFlo

Investigator-sponsored stem cell study for peripheral artery disease approved in Japan

Janssen begins dosing in phase II antidepressant study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...